Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/213623
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Rojas-P, Isabel de | - |
dc.contributor.author | Albiñana, Virginia | - |
dc.contributor.author | Recio-Poveda, Lucía | - |
dc.contributor.author | Rodriguez-Rufián, Amanda | - |
dc.contributor.author | Cuesta, Ángel M. | - |
dc.contributor.author | Botella, Luisa María | - |
dc.date.accessioned | 2020-06-07T07:47:14Z | - |
dc.date.available | 2020-06-07T07:47:14Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Orphanet Journal of Rare Diseases 15(1): 132 (2020) | - |
dc.identifier.uri | http://hdl.handle.net/10261/213623 | - |
dc.description | © The Author(s). | - |
dc.description.abstract | Von Hippel-Lindau syndrome (VHL) is a rare disease of dominant inheritance that increases susceptibility to tumor development, with a complete penetrance at the age of 60. In this report, we present the unprecedented case of a VHL carrier who remains healthy at 72. Under the course of this study, it was discovered that this patient carries a mutation for a second rare disease, Neuronal Ceroid Lipofuscinosis (NCL or CNL). We hypothesize that the CLN mutation she carries offers a protective effect, preventing tumor development in the cells potentially suffering a VHL second hit mutation. To test this hypothesis, we ran a series of molecular experiments and confirmed that cell viability of primary endothelial cells decreases upon CLN5 silencing. Our results further elucidate the cell biology implications of two rare diseases interacting. | - |
dc.description.sponsorship | Funding was provided by the projects SAF2014–52374-R and SAF2017–83351-R from the Ministry of Economy and Competitivity to LMB. The group is part of the CIBER Spanish consortium for Rare Diseases, CIBERER, unit 707, and was also financially supported by the Spanish VHL patient Alliance | - |
dc.language.iso | eng | - |
dc.publisher | BioMed Central | - |
dc.relation | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/SAF2017–83351-R | - |
dc.relation | SAF2017–83351-R/AEI/10.13039/501100011033 | - |
dc.relation.isversionof | Publisher's version | - |
dc.rights | openAccess | - |
dc.subject | Von Hippel-Lindau (VHL) | - |
dc.subject | Neuronal Ceroid Lipofuscinosis type 5 (CLN5) | - |
dc.subject | Rare disease | - |
dc.subject | Hemangioblastoma (HB) | - |
dc.subject | Clear cell renal cell carcinoma | - |
dc.subject | Endothelial cells (ECs) | - |
dc.title | CLN5 in heterozygosis may protect against the development of tumors in a VHL patient | - |
dc.identifier.doi | 10.1186/s13023-020-01410-y | - |
dc.description.peerreviewed | Peer reviewed | - |
dc.relation.publisherversion | https://doi.org/10.1186/s13023-020-01410-y | - |
dc.identifier.e-issn | 1750-1172 | - |
dc.date.updated | 2020-06-07T07:47:15Z | - |
dc.rights.license | http://creativecommons.org/licenses/by/4.0/ | - |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | - |
dc.contributor.funder | Agencia Estatal de Investigación (España) | - |
dc.relation.csic | Sí | - |
dc.identifier.funder | http://dx.doi.org/10.13039/501100011033 | es_ES |
item.languageiso639-1 | en | - |
item.grantfulltext | open | - |
item.fulltext | With Fulltext | - |
Aparece en las colecciones: | (CIB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
CLN5_Rojas_Art2020.pdf | 1,15 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
WEB OF SCIENCETM
Citations
3
checked on 23-nov-2021
Page view(s)
174
checked on 28-mar-2024
Download(s)
101
checked on 28-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons